Our study aimed to identify key differentially expressed genes (DEGs) and miRNAs (DEmiRNAs) which can serve as potential biomarkers for diagnosis and therapy of Alzheimer's disease (AD).
Background
As the most common form of dementia, Alzheimer's disease (AD) is predicted to affect 11.8% of all people globally by 2050 [1]. Alzheimer's disease is a fatal neurodegenerative disorder which can be divided into early onset familial AD (EOAD) and late onset Alzheimer's disease (LOAD) [2] . More than 98% of AD cases are LOAD, which are "sporadic" with no apparent familial recurrence of the disease and typically appears in older individuals (age 65 years and over [3] . It is characterized by progressive neuronal degeneration, pathology of amyloid-b (Ab) deposition (senile plaques, SP), and loss of synapses and formation of neurofibrillary tangles (NFTs) that consist mainly of filaments of hyper-phosphorylated tau [4] .
The Ab precursor protein (APP), apolipoprotein E (APOE), and cleavage of APP by b-secretase or b-site APP cleaving enzyme 1 (BACE1) are indicated to be associated with AD [5, 6] , and APOE4 (E4 allele of apolipoprotein E) is the only verified genetic risk factor for late-onset AD [4, 7] . miRNAs are a class of small non-coding RNAs of 20-22 nucleotides in length, which regulates more than 60% of protein-coding genes [8] and miRNAs are associated with many neurodegenerative diseases, such as AD [9] . Consequently, the research on miRNAs function and the exploration of miRNA replacement therapy is rapidly growing. Researchers have used microarray or high-throughput sequencing technology to detect mRNA and miRNA expression in AD. At present, autopsy is still necessary to diagnose AD accurately [10] . In addition, there is no curative therapy for AD and the current drugs only have limited efficacies [4] . Therefore, identifying non-invasive, accurate, early, and reliable biomarkers is essential for diagnosis and treatment for AD. In this study, through integrated analysis, we aimed to obtain more accurate results than possible with individual study. Functional annotation of DEGs and AD-specific miRNA-target gene network was performed, seeking to identify key DEGs and DEmiRNAs in AD to discover new diagnostic biomarkers for AD.
Material and Methods

Microarray expression profiling in GEO
The Gene Expression Omnibus (GEO) is the largest database of high-throughput gene expression data, developed and maintained by the National Center for Biotechnology Information. The microarray datasets of AD were obtained from the GEO database (http://www.ncbi.nlm.nih.gov/geo). Microarray datasets in blood of AD patients and normal control (NC) group were selected and data with drug stimulation or transfection were excluded. The miRNA datasets were derived from the microarray experiments by Petra-Leidinger et al.
Data analysis
The raw data was preprocessed with background correction. We performed the normalization using the Linear Models for Microarray Data (Limma) package in R. Two-tailed Student's ttest was used to calculate individual P-values, and the Stouffer test was used to merge individual P-values. Multiple comparison correction was performed by Benjamini & Hochberg method to obtain FDR. We finally identified the DEGs with selected criterion of FDR <0.001.
miRNA-target prediction
We used 6 bioinformatic algorithms (RNA22, miRanda, miRDB, miRWalk, PICTAR2, and TargetScan) to predict the putative target genes of differentially expressed miRNAs (DEmiRNAs). The threshold for the targets of DEmiRNAs was those genes predicted by ³4 algorithms. Moreover, verified target genes of DEmiRNAs were obtained by the online tools of miRWalk (http:// www.umm.uni-heidelberg.de/apps/zmf/mirwalk/). MiRNAs down-regulated the expression of its target genes in posttranscription, and the target genes whose expressions were inversely correlated with corresponding miRNAs were selected as miRNA targets with high accuracy based on the obtained gene expression data. Using Cytoscape software (http://www. cytoscape.org/), the miRNA-target gene interaction networks were constructed.
Functional annotation
To analyze the function and the potential pathway of miRNAtarget genes, functional annotation including Gene Ontology (GO) classification (molecular functions, biological processes and cellular component) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment was performed by using the online software GeneCodis (http://genecodis.cnb.csic. es/analysis). FDR<0.05 was defined as statistical significance.
QRT-PCR confirmation
The 6 blood samples were collected from 3 normal control subjects and 3 patients who were diagnosed as having AD. Informed written consent was obtained from all participants, and research protocols were approved by the Ethics Committee of our hospital.
Total RNA was extracted with Trizol reagent (Invitrogen, China). cDNA was generated immediately from 1 μg extracted RNA by using SuperScript ® III Reverse Transcriptase (Invitrogen, China Green PCR Kit (Qiagen, Germany) was used to perform quantitative PCR. Relative gene expression was analyzed using 2 -DDCt method. The human 18srRNA and U6 were used as endogenous controls for mRNA and miRNA expression in analysis.
Results
Differential expression analysis of genes in AD
Three gene expression datasets (GSE63060, GSE63061, GSE18309) and 1 miRNA expression dataset (GSE46579) was enrolled in this study (Table 1) . Twelve DEmiRNAs between the AD and NC groups used in our study were created by PetraLeidinger et al. [11] ( Table 2 ). The panel included 5 down-regulated and 7 up-regulated miRNAs. By integrated analysis (FDR <0.001), 1759 genes displayed altered expression between AD and NC group, with 847 up-regulated genes and 912 down-regulated genes. The top 100 significantly up-regulated or downregulated genes in AD compared to normal controls are displayed in a heat-map (Figure 1 ).
AD-specific DEmiRNA-target interaction network
In total, 784 miRNA-mRNA interaction pairs were obtained, in which 578 miRNA-mRNA pairs included 159 up-regulated miR-NA-mRNA pairs and 419 down-regulated miRNA-mRNA pairs were predicted by more than 4 algorithms. Additionally, 37 upregulated miRNA-mRNA pairs and 169 down-regulated miRNAmRNA pairs were verified by experiments. The miRNA-mRNA regulatory network was constructed based on these miRNAmRNA interaction pairs, which consisted of 10 miRNAs (miR26b-5p, miR-103a-3p, miR-107, miR-26a-5p, let-7f-5p, miR-532-5p, miR-151a-3p, miR-5010-3p, miR-1285-5p, let-7d-3p) and 695 targets differently expressed ( Figure 2 ). MiR-26b-5p (degree=107), miR-103a-3p (degree=88), miR-107 (degree=88) and miR-26a-5p (degree=80) were the top 4 DEmiRNAs covering most DEGs.
Functional annotation
After GO enrichment analysis (FDR <0.05, Table 3 ), the miRNA targets were significantly enriched in regulation of transcription (FDR=7.38E-05), interspecies interaction between organisms (FDR=0.000270215), protein binding (FDR=2.14E-26), and metal ion binding (FDR=2.50E-09). According to the KEGG pathway enrichment analysis (FDR <0.05), several pathways were significantly enriched, including the insulin signaling pathway (FDR=0.0262808), lysosome (FDR=0.0441909), Huntington's disease (FDR=0.0247485, Figure 3) , and basal transcription factors (FDR=0.0216603, Table 4 ). In addition, we found 36 DEGs that were associated with Alzheimer's disease-related metabolic pathways (Table 5 ), among of which 4 genes including low-density lipoprotein receptor-related protein 1 (LRP1) , phospholipase C beta 2 (PLCb2), NDUFA4, and Cyclindependent kinase activator (CDK5R1) were also the targets of DEmiRNAs (Figure 4 ). 
QRT-PCR confirmation
To verify the expression of integrated analysis, we selected 4 DEmiRNAs (miR-26b-5p, miR-26a-5p, miR-107, and miR-103a-3p) and 5 targets LRP1, CDK5R1, PLCb2, NDUFA4, and discs large MAGUK scaffold protein 4 (DLG4). Based on the qRT-PCR results, the expression of LRP1, CDK5R1, and NDUFA4 were down-regulated, while the other 5 were up-regulated in AD compared to NC. The expression of miR-26b-5p, miR-26a-5p, LRP1, and CDK5R1 was inconsistent with results of our integrated analysis ( Figure 5 ). .38E-12   COX4I1, NDUFA8, ATP5J, NDUFAB1, ITPR3, COX7C, NDUFV2,  ATP5F1, ATP5D, NDUFS4, COX6A1, FAS, LRP1, COX5B, PLCB2,  ATP5H, NDUFB3, NAE1, NDUFA4, NCSTN, NDUFB6, UQCRC2,  ATP5C1, NDUFA9, COX7A2, COX7B, UQCRB, NDUFA1, CDK5R1,  NDUFB2, COX6C, ATP5O, NDUFB5 , NDUFS3, UQCRH, UQCRQ Table 5 . Differently expressed genes enriched in pathway of Alzheimer's disease. 
KEGG ID KEGG term
Count FDR Genes hsa05010 Alzheimer's disease 36 1
Discussion
As the principal cognitive problem in humans, the incidence rate of AD increased significantly with the aging population.
Since there is no cure for it, finding novel strategies of treatment for AD has long been a central goal. In this study, we performed miRNA and mRNA integrated analysis (MMIA), and obtained 1759 DEGs and 12 DEmiRNAs in blood of AD patients compared to NC. According to the functional annotation and AD-specific DEmiRNA-target interaction network, 5 DEGs (LRP1, PLCb2, NDUFA4, CDK5R1, and DLG4) upon the regulation of 4 DEmiRNAs (miR-26b-5p, miR-26a-5p, miR-107, and miR-103a-3p) were associated with AD.
Neuritic plaques (NP) and neurofibrillary tangles (NFT) in the brain are 2 major hallmarks of AD [12] . LRP1 is an APOE receptor in the brain. APOE can regulate the free cholesterol levels of neurons via LRP1, thereby mediating the APOE4 effect of NFT formation. Additionally, altered cholesterol metabolism significantly contributes to neuronal damage and to progression of AD. Hence, LRP1 may play a key role in the pathogenesis of AD by regulating cholesterol metabolism and NFT formation. Up-regulated LRP1 has been found in neurons in the hippocampus of AD patients [13, 14] . According to our integrated analysis, LRP1 was up-regulated in the blood of AD patients. However, LRP1 was down-regulated in blood of patients with AD in our q-RT-PCR expression confirmation. The precise role of LRP1 in AD needs further research.
CDK5R1 encodes p35s, which is necessary for activation of CDK5. P35s can be cleaved into its more stable and truncated form, termed p25, and increased production of p25 enhances the activity of CDK5 [15] . With abnormal hyperphosphorylation of tau by activated CDK5, the numbers of NFTs which mainly composed of hyperphosphorylated microtubule associated protein tau was increased. Thus, the up-regulated CDK5R1 may increase the risk of AD by elevating the activation of CDK5, hyperphosphorylation of tau, and the formation of NFTs [16] . In our study, CDK5R1 was up-regulated in AD, which was shown to have the same pattern in a previous study [17] . In addition, increased p25 is associated with upregulation of Ab and accumulation of intra-neuronal Ab, which are other major traits of AD [18] .
NDUFA4 encodes a protein in the respiratory chain of mitochondria [19, 20] . It has both NADH dehydrogenase activity and oxidoreductase activity [21] . Deficiency of complex I was found in various tissues of patients with neurodegenerative diseases like AD and Parkinson's disease [22] . In our study, NDUFA4 was down-regulated in AD, and it may be associated with the pathogenesis of AD via regulation in the respiratory chain of mitochondria.
DLG4 (also known as PSD95) is associated with anchoring glutamate receptors into the postsynaptic membrane [23] .
Abnormally expressed DLG4 presumably leads to disturbance of glutamatergic neurotransmission. In addition, DLG4 is involved in regulating amyloid-b deposition [23] . Up-regulated DLG4 was detected in AD in our study, indicating its important role in AD, and up-regulated DLG4 might serve as a biomarker for AD.
Both extracellular and intracellular elevation of Ca2 + are associated with the neurodegeneration in AD [24] . PLC (phosphoinositide-specific phospholipase C) is a major pathway activated by elevated intracellular calcium. As a member of the PLC family, PLCb2 is activated by G proteins, and generates calcium signals in cells [25] . In our study, PLCb2 was up-regulated in AD, which may have an important role in the progression of AD. Based on this, we may be able to develop a new therapeutic strategy.
According to the KEGG enrichment analysis, NDUFA4, PLCb2, and DLG4 were enriched in another neurodegenerative disorder, Huntington's disease, emphasizing the importance of these 3 genes in AD as well. Moreover, PLCb2, CDK5R1, NDUFA4, and LRP1 were found to be enriched in the pathway of AD, which supports our findings.
Rod-like structures were found in AD patients, which consisted of actin and the actin-binding protein cofilin [26] . Both miR103 and miR-107 have inhibitory effect on the translation of cofilin, so reduced miR103 and miR-107 may induce AD by exerting promotive effects on the level of protein cofilin and formation of rod-like structures. In addition, a correlation between NP counts, NFT counts, and decreased miR-107 expression was discovered [27] . Down-regulated MiR-107 was detected in the temporal cortical gray matter of humans in the early progression of AD and down-regulated miR-103a-3p has 
